Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recommended as one of the best cheap stocks for beginners. Analyst Evan Seigerman from BMO Capital maintains a Buy rating with a $640.00 price target. The positive outlook is supported by promising Phase 3 trial results for allergy antibody cocktails targeting cat and birch allergies, showing significant symptom reductions. These results indicate strong clinical efficacy to address unmet allergy treatment needs. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) develops therapies for various diseases, including cancer, eye disorders, and allergies, with key products Dupixent and Eylea driving growth. Dupixent, a treatment for eczema, is co-owned with Sanofi, while Eylea, for wet age-related macular degeneration, is co-marketed with Bayer. While REGN shows potential, some AI stocks may offer greater upside with lower risk. For more insights, check out the best short-term AI stock recommendations.

Read more at Yahoo Finance: BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT